NCT07029139View on ClinicalTrials.gov

A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

March 1, 2029

Conditions
Primary Membranous Nephropathy
Interventions
DRUG

JMT601 Injection

In accordance with the protocol

DRUG

Rituximab

In accordance with the protocol

DRUG

Cyclosporin Capsules

In accordance with the protocol

All Listed Sponsors
lead

Shanghai JMT-Bio Inc.

INDUSTRY